The outcomes of glucose abnormalities in pre-diabetic chronic hepatitis C patients receiving peginterferon plus ribavirin therapy
Liver International, 07/02/2012
Clinical Article
Huang JF et al. – Successful eradication of chronic hepatitis C virus (HCV) improves glucose abnormalities in pre–diabetic chronic hepatitis C (CHC) patients.
Methods- Chronic Hepatitis C patients with a baseline haemoglobin A1C (A1C) range 5.7–6.4% who achieved 80/80/80 adherence were prospectively recruited.
- All patients received current peginterferon–based recommendations.
- The primary outcome measurement was their A1C level at the end of follow–up (EOF).
- The interaction between variants of the IL28B gene and outcomes of glucose metabolism was also measured.
- A total of 181 consecutive CHC patients were enrolled.
- The mean A1C at EOF was 5.82 ± 0.41%, which was significantly lower than the baseline level (5.93 ± 0.21%, P < 0.001).
- At EOF, 63 (34.8%) patients became normoglycaemic, whereas 10 (5.5%) patients developed DM.
- The sustained virological response (SVR) rates of 63 normoglycaemics, 108 pre–diabetics and 10 diabetic patients at the EOF were 92.1%, 84.3% and 50% respectively (normoglycaemics vs. diabetics P=0.003; pre–diabetics vs. diabetics P = 0.02).
- Achievement of an SVR was the only predictive factor associated with normoglycaemia development at EOF by multivariate logistic regression analysis (Odds ratio=2.6, P=0.04).
- The prevalence of the interleukin 28B rs8099917 TT variant in patients who developed DM (70.0%) at EOF tended to be lower than that in patients with pre–diabetics (87.0%) or normoglycaemics (92.1%).
